Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 88

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 88
---
 with market and service conditions granted to the Company’s CEO, the remaining stock options granted during the periods presented in the table have only service-based criteria and vest over four years. 

F-31

Restricted Stock UnitsThe Company grants RSUs to members of its board of directors and employees. The following table summarizes the Company’s RSU activity for the period indicated:   

        For the Year Ended December 31, 2024

        Weighted-Average

        Grant Date

        Shares

        Fair Value

        Grants outstanding at beginning of the period

        2,240,504
         
        (1)
        $
        120.17

        Granted

        1,409,347
         
        (2)
         
        129.31

        Vested

        (734,922
        )

        107.93

        Forfeited

        (197,515
        )

        126.19

        Grants outstanding at end of the period

        2,717,414

        $
        127.78

      (1) Included in RSUs outstanding at the beginning of the year ended December 31, 2024 are 33,000 shares of PSUs (the “March 2022 PSU”) with performance conditions related to regulatory approval of certain of the Company's product candidates and 485,275 shares of PSUs (the “March 2023 PSU”) with performance conditions related to regulatory approval of certain of the Company's product candidates and the achievement of a certain financial performance target. (2) Included in RSUs granted during the year ended December 31, 2024 are 97,460 shares with performance conditions (the “March 2024 PSU”), which are related to the achievement of certain financial performance targets and regulatory approval of certain of the Company's product candidates and 24,500 shares of the March 2023 PSU, which are related to the achievement of a certain financial performance target. Stock options and the remaining RSUs granted during the year ended December 31, 2024 have only service-based criteria and vest over four years. As of December 31, 2024, the following PSUs became vested or eligible for vesting:•March 2022 PSU: The expanded regulatory approval of ELEVIDYS in June 2024 resulted in 33,000 shares becoming eligible for vesting, which is contingent on the fulfillment of remaining service conditions.•March